rss
DTB 42:18-21 doi:10.1136/dtb.2004.42318
  • Articles

Are Seretide and Symbicort useful in COPD?

  • Relevant BNF section: 3.2

Abstract

Seretide (fluticasone + salmeterol - Allen & Hanburys) and Symbicort (budesonide + formoterol - AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations.13 Advertising for Seretide depicts a man and states that the drug "has improved his ability to breathe and reduced his risk of exacerbations", while promotional claims for Symbicort include benefits in "reducing symptoms" and "improving quality of life". Here we assess the place of these fixed-dose combination inhalers containing a corticosteroid and a long-acting beta2 agonist in the management of patients with COPD.

Footnotes

    Free sample issue

    This DTB issue is free to all users to allow everyone the opportunity to see the full scope and typical content published in the bulletin.

    View free sample issue >>

    DTB now online first!

    Sign up to receive email alerts when new content is published online before it appears in print.

    Navigate This Article